Aldeyra Therapeutics, Inc.: AQR CAPITAL MANAGEMENT LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
AQR Capital Management LLC amended its Schedule 13G filing on Aldeyra Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001167557-26-000229. The amendment signals a change in the institutional investor's position in the clinical-stage biotech, though the filing summary did not disclose the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts around the 5% threshold, making the update a potential indicator of shifting institutional conviction. Investors will watch for the full filing details to see whether AQR increased or trimmed its stake and at what levels.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aldeyra Therapeutics, Inc., AQR Capital Management LLC